Calliditas Therapeutics (CALT) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Calliditas Therapeutics AB has announced a change in its number of shares and votes following the exercise of warrants from incentive programs initiated in 2020 and 2021. This has led to an increase in share capital and total shares, which now stand at 59,941,465 with an equivalent number of votes. The company, known for its focus on orphan renal and hepatic diseases, is listed on both Nasdaq Stockholm and the Nasdaq Global Select Market.
For further insights into CALT stock, check out TipRanks’ Stock Analysis page.